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Abstract
Background: Relatives of BRCA1 and BRCA2 mutation carriers have long been proposed by
epidemiological studies to have an increased risk of developing prostate cancer. In the Ashkenazi
Jewish (AJ) population, the existence of 3 frequent founder mutations, 185delAG and 5382insC in
BRCA1 and 6174delT in BRCA2 greatly facilitates screening for carriers.
Methods: We tested 146 AJ men with confirmed diagnoses of invasive prostate cancer. Thirteen
had at least one first degree relative with prostate cancer. The median age at diagnosis of
participants was 67.9 years (range 48.6–84.2 years). Subjects were screened for the
BRCA1:185delAG,  BRCA1:5382insC and BRCA2:6174delT mutations simultaneously using a
multiplex sizing assay detecting band shifts in the presence of the variant sequence.
Results: Two out of 146 individuals were found to carry the germline BRCA2 mutation 6174delT
(1.4%); the previously reported population frequency for this mutation is ~1% in AJ. We found no
BRCA1 mutations. One carrier had 2 uncles affected with prostate cancer, while the other had an
uncle and daughter with breast cancer. We combined our results with previously published data
examining these 3 founder AJ mutations in men with prostate cancer and in population controls.
Including our results, studies to date reported 5/463 (1.1%), 2/293 (0.68%) and 7/461 (1.3%)
carriers for the BRCA1:185delAG, BRCA1:5382insC and BRCA2:6174delT mutations in prostate
cancer cases, respectively. This compares with combined reported frequencies of 85/9371 (0.91%),
24/8867 (0.27%) and 119/9514 (1.3%) for the same mutations in control individuals. There was no
statistically significant excess of mutations in cases compared to controls in either gene.
Conclusions: Our observations remain preliminary. By combining all studies published to date, we
have an 80% power to detect ORs of 2.7, 6.6 and 2.5 (185delAG, 5382insC and 6174 delT,
respectively) while the values we observed range between 1.0 and 2.5. However, the contribution
of rare mutations with such low odds ratios to the population prostate cancer burden is unlikely
to be large enough to be clinically useful. Thus, contrary to suggestions from some previous
epidemiological data, our observations do not support an important role for AJ founder BRCA1/2
mutations in prostate cancer risk.
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Background
Mutations in the BRCA1 and BRCA2 genes are responsible
for a large proportion of inherited breast and ovarian can-
cer cases. Both BRCA1 and BRCA2 comprise many exons
and hundreds of specific mutations have been identified
to date in these 2 large genes (Breast Cancer Information
Core website). This makes screening for mutations in
individuals at risk a time consuming task that complicates
mutation testing for large numbers of samples.
For over 2000 years, Jews have been a migratory people
linked by religion, language, customs and culture, and
have been establishing communities throughout the Mid-
dle East and the Mediterranean basin (reviewed in [1]).
This has resulted in the creation of a Jewish genetic iden-
tity which evolved over time, partly through genetic drift
and partly due to bottlenecks resulting from wars or epi-
demics, often followed by rapid population growth
thanks to large family sizes. This genetic identity is charac-
terized by the existence of some 40 genetic conditions
with Mendelian patterns of transmission with established
allele frequencies within distinct Jewish groups. In
Ashkenazi Jews, two founder mutations in BRCA1
(185delAG, population frequency ~1%, 5382insC,
~0.13%) and one founder mutation in BRCA2 (6174delT,
population frequency ~1%) [2–4], greatly facilitate
screening of individuals at risk for breast and ovarian
cancer.
Previous studies have suggested an increased risk of pros-
tate cancer in relatives of BRCA1 and BRCA2 mutation car-
riers or in mutation carriers themselves [5–11]. When
comparing  BRCA1  and  BRCA2  carriers in similarly
designed studies, the risk of prostate cancer appears to be
lower in BRCA1 carriers [11] than in BRCA2 carriers [10],
and mostly confined to early-onset prostate cancer cases.
Prostate cancer is a common malignancy, and identifying
individuals at risk of developing the disease could be of
clinical importance. Therefore, we attempted to deter-
mine the contribution of germ-line BRCA1/2 mutations to
the risk of prostate cancer by testing a group of unselected
AJ prostate cancer cases for the 3 founder mutations.
Methods
Study Population
Following IRB approval, we used hospital-based registries
to identify 435 self-reported AJ men with prevalent pros-
tate cancer, diagnosed between 1991 and 2002, who were
known to be alive in 2002. Patients were considered
Ashkenazi Jewish if both parents were reported as
Ashkenazi Jewish, with no Sephardic heritage. Individuals
not fulfilling these criteria were excluded. All were diag-
nosed and/or treated in one of three large McGill Univer-
sity affiliated hospitals in metropolitan Montreal,
Canada. The diagnosis of invasive prostate cancer was
confirmed by examining pathology reports from patients'
medical charts. At the time of writing, 250 patients had
been contacted (reasons for lack of contact: physician
approval pending, returned unopened letters, address
unknown, left town). Of these, 205 responded to our let-
ter; 48 refused and 157 agreed to participate in the study.
One-hundred-and-forty-six had provided a blood sample
for this study at the time of analysis and were genotyped
for two BRCA1 and one BRCA2 AJ founder mutations,
making this the largest series of AJ prostate cancer cases
studied thus far. All participants were given the option of
receiving genetic counseling.
Thirteen cases had a family history (at least one first
degree relative with prostate cancer) (8.9%); a single
proband was included in the study from each family with
multiple prostate cancer cases. The median age at diagno-
sis of participants was 67.9 years (range 48.6–84.2 years)
and the participants were tested at a median of 5.7 years
since diagnosis (range 0.3–23.7 years, 5 cases had missing
information). Overall, 75/146 participants (51.4%) were
found to have a Gleason score of 6/10 or greater (median
number of months since diagnosis = 55) and 53/146
(36.35%) were found to have a Gleason score of 5 or less
(median number of months since diagnosis = 78). This
difference in the time interval between diagnosis and
blood collection, dichotomized at a Gleason score of 6, is
statistically significant (P = 0.042, Mann-Whitney U-test,
2-sided). However, when we regressed the Gleason score
against the time interval in months between the date of
diagnosis and blood draw, there was no evidence for an
effect across all scores. The correlation coefficient (r) was
-0.037 (r2 = 0.0013, P = 0.68). We do not have a Gleason
score for 18 men (12.3%, median number of months
since diagnosis = 96).
Molecular Analysis
We screened for founder BRCA1/2 mutations using a mul-
tiplex sizing assay in which all 3 PCR products can be vis-
ualized on a single polyacrylamide gel as described
previously by Kuperstein et al [12]. Samples demonstrat-
ing a band shift were re-amplified and run again for con-
firmation. All tests included a positive control previously
confirmed by sequencing.
Results and Discussion
We observed 2 BRCA2  6174delT mutations and no
BRCA1 mutations (Table 1). One carrier, diagnosed at age
56 with a Gleason score of 7/10, had two uncles with
prostate cancer; the second carrier, diagnosed at age 76
with a Gleason score of 9/10, had no relatives with pros-
tate cancer but had an uncle and a daughter with breast
cancer (Figure 1).BMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/7
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Recent studies reporting BRCA1/2 founder mutation fre-
quencies in unselected AJ men with prostate cancer have
also failed to find an excess of carriers among affected
individuals [13–15], with the exception of one study [16]
where a slight but significant excess of BRCA1:5382insC
carriers was observed. However, all studies were small,
and lack of power may have prevented some differences
from being detected. We therefore combined our results
with observations in cases and, when available, controls
from these studies. In addition, we compiled data from
various reports which previously examined mutation fre-
quencies in unselected AJ population controls [2–4] and
AJ volunteers [8]. There were no statistically significant
differences between the frequencies of the founder muta-
tions in individuals affected with prostate cancer com-
pared with their frequencies in AJ population controls
(Table 1).
Different recruitment methods were used by the various
groups cited in Table 1 as sources of controls. Hubert et al
[14] selected a group of 87 healthy elderly Israeli men
(median age 71 years) with no history of cancer as con-
trols, thereby attempting to compensate for possible age-
related variations in mutation frequencies. The larger pop-
ulations studies [2–4] performed mutation testing on AJ
individuals from either the US or Israel (or both) who
were referred for unrelated genetic testing (e.g. Tay Sachs,
Cystic Fibrosis, Fanconi Anemia, etc.), with no informa-
tion available on gender, age or cancer history for these
participants. Since genetic testing for the recessive condi-
tions listed above would usually be undertaken prior to
making the decision of having children, this larger group
is more likely to have a lower median age than that
observed in prostate cancer cases. This group should,
however, otherwise provide representative population fre-
quencies for the mutations. Finally, controls from Struew-
ing et al [8] were AJ volunteers from the Washington D.C.
area who wished to participate in a study on breast and
ovarian cancer. The authors acknowledge that such a
recruitment scheme led to a higher than expected propor-
tion of participants reporting a personal or family history
of breast and ovarian cancer. This may conceivably result
in an exaggerated mutation frequency in this control
group compared to frequencies in the general population.
In addition, participants in this control group included a
number of siblings and relatives, including some who
were mutation carriers, potentially further increasing the
apparent frequency of BRCA1 and BRCA2 mutations in
this cohort. We therefore compared the mutation frequen-
cies in volunteers from the Washington D.C. area [8] to
frequencies obtained from combining results from our
other sources of controls [2–4,14] to determine if frequen-
cies from the volunteer group were different from those
from the general population. Frequencies for
BRCA1:185delAG and BRCA2:6174delT were slightly
lower in the volunteer group, although the difference was
not statistically significant. In contrast, the
BRCA1:5382insC mutation was significantly over-repre-
sented in volunteer controls compared to random popu-
lation controls (OR = 3.3, 95%CI: 1.1–13; P = 0.02). In
consequence, we compared our combined cases to con-
trols once again, this time excluding control data from the
Table 1: BRCA1/2 founder mutation frequencies in AJ unselected prostate cancer cases and controls
Ref # 185delAG (%) 5382insC (%) 6174delT (%)
Cases
Lehrer et al (1998) 13 0/60 n.t. 0/60
Hubert et al (1999) 14 2/87 (2.3%) 0/87 1/87 (1.1%)
Nastiuk et al (1999) 15 1/83 (1.2%) n.t. 2/82 (2.4%)
Vazina et al (2000) 16 2/87 (2.3%) 2/60 (3.3%)* 1/86 (1.1%)
Hamel et al (this study) 0/146 0/146 2/146 (1.4%)
Total 5/463 (1.1%) 2/293 (0.68%) 6/461 (1.3%)
Controls
Struewing et al (1995) 2 8/858 (0.93%) 0/433 n.t.
Roa et al (1996) 3 34/3108 (1.1%) 4/3116 (0.13%) 47/3085 (1.5%)
Oddoux et al (1996) 4 n.t. n.t. 12/1255 (0.96%)
Struewing et al (1997)† 8 41/5318 (0.77%) 20/5318 (0.38%) 59/5087 (1.2%)
Hubert et al (1999) 14 2/87 (2.3%) 0/87 1/87 (1.1%)
Total 85/9371 (0.91%) 24/8867 (0.27%) 119/9514 (1.3%)
Overall OR (95%CI) 1.2 (0.38–2.9) 2.5 (0.29–10) 1.0 (0.37–2.4)
P Value (2-sided) 0.62 0.20 0.83
n.t. Not tested Odds ratios were calculated according to the method of Gart. 95% confidence intervals were calculated using the exact Clopper-
Pearson method and P values are two-sided Fisher exact tests. *This frequency was reported as significantly different from observations in a control 
population in the original publication. †Data from this publication were used as control by Vazina et al, 2000.BMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/7
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Washington D.C. study. While there was no change for
BRCA1:185delAG and BRCA2:6174delT, we now
observed a stronger association between the low fre-
quency BRCA1:5382insC mutation and prostate cancer
(OR = 6.1, 95%CI: 0.54–42; P = 0.07). However, as indi-
cated by the wide confidence interval, this effect is driven
entirely by 2 carriers observed by Vazina et al [16], the
only report of BRCA1:5382insC mutations among pros-
tate cancer cases across 3 studies. According to the
authors, neither carrier has a family history of prostate
cancer.
It is difficult to reconcile our observations with results
from previous epidemiological studies suggesting an
increased prostate cancer risk in relatives of mutation car-
riers [5–11]. One possible explanation may be that a diag-
nostic bias exists in families where hereditary cancer cases
are found. Specifically, having a relative affected with
BRCA1/2-related breast or ovarian cancer may encourage
relatives to undergo testing and reveal the existence of
prostate tumors which may otherwise have remained
asymptomatic and undetected, thereby artificially increas-
ing the incidence of prostate cancer cases in families bear-
ing BRCA1/2 mutations.
If there were a significant decline in the mutation fre-
quency of founder BRCA1 and/or BRCA2 mutations in
older Jewish males, then it is possible that using frequen-
cies of 0.91% for BRCA1:185delAG, 0.27% for
BRCA1:5382insC and 1.3% for BRCA2: 6174delT (Table 1)
from a potentially younger population will result in an
underestimation of the odds ratios observed. There are no
data published that address this possibility, but if we
assume that age-matched controls would have overall
allele frequencies of 0.64%, 0.19% and 0.91% (observed
frequencies decreased by 30%) for the 185delAG,
Pedigrees of the 2 BRCA2:6174delT mutation carriers Figure 1
Pedigrees of the 2 BRCA2:6174delT mutation carriers. Probands are identified with an arrow. PSU = primary site unkown; 
TAHBSO = total abdominal hysterectomy with bilateral salpingo-oophorectomy.
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5382insC and 6174delT alleles, respectively, then using
the cases and controls in Table 1 we still do not reach
statistical significance for an association between founder
mutations and prostate cancer: BRCA1:185delAG, OR =
1.7 (P = 0.23); BRCA1:5382insC, OR = 3.6 (P = 0.12);
BRCA2:6174delT, OR = 1.4 (P = 0.33). Thirty percent is a
generous reduction; these results suggest that a bias due to
an age-related decline in mutation frequency in the con-
trol population is unlikely to be a major explanatory
factor.
A third possibility is that only certain BRCA1/2 mutations
are associated with an increased prostate cancer risk. In
the initial report from the Breast Cancer Linkage Consor-
tium [10], there was a significant excess risk of prostate
cancer for male BRCA2 mutation carriers (RR: 4.65, 95%
CI: 3.48–6.22). In a further analysis, Thompson et al [17]
found that the risk of prostate cancer was lower in carriers
of BRCA2 mutations located in the ovarian cancer cluster
region (OCCR; nucleotides 3035–6629, including the AJ
founder 6174delT) than in carriers of mutations cluster-
ing elsewhere in the gene (RR = 0.52; 95%CI = 0.24–1.00;
P = 0.05). This observation was recently indirectly sup-
ported by a large study examining 263 men with early-
onset prostate cancer (55 years and less) where the
authors sequenced the entire BRCA2 coding region and
found 6 truncating mutations, all located outside the
OCCR [18]. However, this hypothesis cannot explain dis-
crepancies in findings between epidemiological and direct
mutation detection studies where an increased prostate
cancer risk was also observed in relatives of AJ founder
mutation carriers, including BRCA2:6174delT [9]. It is
notable, however, that in the study of Warner et al. [9], a
significant difference in cumulative incidence of prostate
cancer to age 85 (33.6% vs. 12.6%, P  = 0.049) was
observed when comparing relatives of women with and
without founder BRCA1/2  mutations, who were them-
selves affected by breast cancer. Thus other factors may
account for the differences in prostate cancer incidence
observed.
With the combined results from nine studies, we have an
80% power to detect ORs of 2.7, 6.6 and 2.5 (185delAG,
5382insC and 6174 delT, respectively), while the values
we observed range between 1.0 and 2.5. Therefore, we do
not have the power to rule out small effects even with our
combined sample size. For a mutation with a population
frequency near 1%, we would need more than 3,200 cases
and 3,200 controls to rule out an OR of 2.0 or greater; over
10,000 cases and 10,000 controls would be needed to
exclude an OR of 1.5 or greater. These numbers indicate
that larger studies will be needed to rule out a small effect
by BRCA1/2 founder mutations on prostate cancer risk.
However, using the observed mutation frequency in con-
trols, we can estimate the population attributable risk per
cent (PAR%) of these mutations as follows:
PAR% = Pe (RR-1)/ [1 + Pe(RR-1)] × 100
where Pe = proportion of exposure in controls and RR =
observed relative risk between cases and controls. PAR%
values will reflect the proportion of prostate cancer cases
attributable to these AJ founder mutations based on their
frequency in the population; from the combined data in
Table 1, these values are 0.18% (BRCA1:185delAG),
0.40% (BRCA1:5382insC) and 0% (BRCA2:6174delT). In
comparison, based on previously published data on cases
diagnosed after 55 years of age [19,20], the PAR% of AJ
BRCA1 (185delAG and 5382insC combined) and BRCA2
(6174delT) founder mutations are 3.8% and 2.5 %,
respectively, in the case of breast cancer, and 23.8% and
16.7%, respectively, in the case of ovarian cancer.
Conclusions
We screened 146 AJ men with prostate cancer for germline
AJ BRCA1/2 founder mutations, and found only two car-
riers of the BRCA2:6174delT mutation. As was the case in
previous smaller studies, our observations failed to sup-
port previous data suggesting that AJ founder BRCA1/2
mutations might contribute significantly to prostate can-
cer risk. While even the combined results of publications
to date do not have the power to rule out a small effect,
PAR percentages above do not support a major role for
these founder mutations in prostate cancer susceptibility.
Any modest but statistically significant contribution of
these three mutations to prostate cancer risk that may be
uncovered using larger studies is unlikely to be of clinical
significance.
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